Diagnostic value of 18F-FDG PET/CT in patients with carcinoma of unknown primary
-
摘要:
目的探讨18F-FDG PET/CT在不明原发癌(CUP)患者中的临床作用。 方法选择2018年3月~2019年8月经临床诊断为CUP的121例患者，其中男性79例、女性42例，年龄30~86岁(63±12岁)，回顾性分析其全身18F-FDG PET/CT显像结果。本研究的最终诊断均通过病理证实或临床随访证实。 结果18F-FDG PET/CT显像成功在121例患者中检出原发性肿瘤59例(49%)。18F-FDG PET/CT显像检测出最常见的原发肿瘤是肺癌(n=31)。1例患者在18F-FDG PET/CT显像中发现两种原发性肿瘤(前列腺癌和结肠癌)，肺活检显示此患者为前列腺癌，结肠癌被认为是同步的第二原发肿瘤。11例18F-FDG PET/CT显像结果为假阳性。51例患者在18F-FDG PET/CT显像中未能检测到任何原发肿瘤病灶，其中有11例患者在临床随访中检测到原发肿瘤病灶，因此认为假阴性。18F-FDG PET/CT检测原发性肿瘤的敏感性、特异性和准确性分别为84%、78%和82%。 结论全身18F-FDG PET/CT显像是检测CUP病灶原发肿瘤的可靠方法。除了发现原发性肿瘤外，还可帮助确定疾病的程度，并有助于患者的临床管理。 -
关键词:
- 氟脱氧葡萄糖 /
- 正电子发射断层扫描/计算机断层扫描 /
- 转移 /
- 不明原发癌
Abstract:ObjectiveTo investigate the diagnosis value of 18F-FDG PET/CT in patients with carcinoma of unknown primary (CUP). MethodsA total of 121 patients(79 males,42 females, age range 30-86 years) with a diagnosis of CUP who underwent whole body 18F-FDG PET/CT imaging were included in this retrospective study from March 2018 to August 2019. The final diagnoses were confirmed either histopathologically or by clinical follow-up. ResultsThe 18F-FDG-PET/CT successfully detected the primary tumor in 59 out of 121 (49%) patients. The most common primary tumor as detected by 18F-FDG PET/CT was lung cancer (n=31). In a patient, two primary tumors (colon and prostate) were detected on PET/CT imaging. Lung biopsy revealed prostate cancer in this patient and the colon cancer was accepted as a synchronous second primary tumor. 18F-FDG PET/CT findings were false-positive in 11 patients. 18F-FDG PET/CT could not detect any primary lesion in 51 patients, whose conventional work-up detected a primary tumor in 11 and thus considered as false-negative. The sensitivity, specificity rate and accuracy of 18F-FDG PET/CT in detection of primary tumor were identified as 84%, 78% and 82%, respectively. Conclusion18F-FDG PET/CT of total body is an effective method for detecting the primary tumor in patients with CUP. In addition to detect the primary tumor, it can help determine disease extent and contribute to patient management. -
Key words:
- FDG /
- PET/CT /
- metastasis /
- carcinoma of unknown primary
-
图 1 经肺活检确诊为转移的CUP患者的18F-FDG PET/CT图像
A: MIP; B: 肺部转移; C,D: 两处结肠病灶; E: 前列腺病灶。最终确诊为结肠腺癌，结肠绒毛管状腺瘤癌变及前列腺癌。
Figure 1. 18F-FDG PET/CT images of CUP patients diagnosed with metastasis by lung biopsy
-
[1] Pavlidis N, Fizazi K. Carcinoma of unknown primary[J]. Crit Rev Oncol Hematol, 2009, 69(3): 271-8. doi: 10.1016/j.critrevonc.2008.09.005 [2] Kwee TC, Basu S, Cheng G, et al. FDG PET/CT in carcinoma of unknown primary[J]. Eur J Nucl Med Mol Imaging, 2010, 37(7): 635-44. [3] Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of unknown primary[J]. Eur J Cancer, 2003, 39(18): 1990-2005. [4] Chorost MI, Lee MC, Yeoh CB, et al. Unknown primary[J]. J Surg Oncol, 2004, 15, 87(2): 191-203. [5] Haas I, Hoffmann TK, Engers R, et al. Diagnostic strategies in cervical carcinoma of an unknown primary[J]. Eur Arch Otorhinolaryngol, 2002, 259(2): 325-33. [6] Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology[J]. JAMA, 2003, 290(20): 3199-206. [7] Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI[J]. Gynecol Oncol, 2010, 116(4): 389-94. [8] Shim SS, Lee KS, Kim BT, et al. Nonsmall cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging[J]. Radiology, 2005, 236(12): 1011-9. [9] Sève P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site[J]. Cancer, 2007, 109(3): 292-9. [10] Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor[J]. Cancer, 2004, 101(31): 2641-9. [11] Delgado RC, Fernández-Pérez C, González-Maté A, et al. Meta analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors[J]. J Nucl Med, 2003, 44(11): 1301-4. [12] Yanpar Z, Kibar M, Yapar AF, et al. The value of 18F-fluorodeoxyglucose positron emission tomography/compuied tomography in carcinoma of an unknown primary: diagnosis and follow-up[J]. Nucl Med Commun, 2010, 31(1): 59-66. doi: 10.1097/MNM.0b013e328332b340 [13] Chorost MI, Lee MC, Yeoh CB, et al. Unknown primary[J]. J Surg Oncol, 2004, 87(4): 191-203. doi: 10.1002/jso.20099 [14] Gutzeit A, Antoch G, Kühl H, et al. Unknown primary tumors:detection with dual-modality PET/CT--initial experience[J]. Radiology, 2005, 234(3): 227-34. [15] Lee JR, Kim JS, Roh JL, et al. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study[J]. Radiology, 2015, 274(8): 764-71. [16] Lonneux M, Reffad A. Metastases from unknown primary tumor. PET-FDG as initial diagnostic procedure[J]. Clin Positron Imaging, 2000, 3(5): 137-41. [17] Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor[J]. Cancer, 2004, 101(12): 2641-9. [18] Bohuslavizki KH, Klutmann S, Kröger S, et al. FDG PET detection of unknown primary tumors[J]. J Nucl Med, 2000, 41(6): 816-22. [19] Han A, Xue J, Hu M, et al. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary[J]. Cancer Epidemiol, 2012, 36(2): 470-5. [20] Riaz S, Nawaz MK, Faruqui ZS, et al. Diagnostic accuracy of 18F-Fluorodeoxyglucose positron emission tomography-computed tomography in the evaluation of carcinoma of unknown primary[J]. Mol Imaging Radionucl Ther, 2016, 25(6): 11-8. [21] Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site[J]. Q J Nucl Med Mol Imaging, 2006, 50(4): 15-22. [22] Wang G, Wu Y, Zhang W, et al. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary[J]. J Med Imaging Radiat Oncol, 2013, 57(2): 65-71. [23] Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis[J]. Eur Radiol, 2009, 19(5): 731-44. [24] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005 [25] Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology[J]. J Nucl Med, 2008, 49(19): 480-508. [26] Elboga U, Kervancioglu S, Sahin E, et al. Utility of 18F-fluorodeoxyglucose positron emission tomography/computed in carcinoma of unknown primary[J]. Int J Clin Exp Pathol, 2014, 7(12): 8941-6. -
下载:
点击查看大图
图(2)
计量
- 文章访问数: 891
- HTML全文浏览量: 373
- PDF下载量: 14
- 被引次数: 0
